These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Parkinson's disease: diagnosis and treatment. Rao SS; Hofmann LA; Shakil A Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710 [TBL] [Abstract][Full Text] [Related]
3. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Mercuri NB; Bernardi G Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832 [TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease: making the diagnosis, selecting drug therapies. Scharre DW; Mahler ME Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845 [TBL] [Abstract][Full Text] [Related]
5. [Current treatment strategies for Parkinson's disease]. Südmeyer M; Wojtecki L; Schnitzler A Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168 [No Abstract] [Full Text] [Related]
6. Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F; Riuggeri RM J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625 [TBL] [Abstract][Full Text] [Related]
7. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073 [TBL] [Abstract][Full Text] [Related]
8. Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Bhatia K; Brooks DJ; Burn DJ; Clarke CE; Playfer J; Sawle GV; Schapira AH; Stewart D; Williams AC Hosp Med; 1998 Jun; 59(6):469-80. PubMed ID: 9775275 [TBL] [Abstract][Full Text] [Related]
9. Management for motor and non-motor complications in late Parkinson's disease. Chan DK; Cordato DJ; O'Rourke F Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's goal: ease symptoms, slow progression. Johns Hopkins Med Lett Health After 50; 2006 Jun; 18(4):4-5. PubMed ID: 16795901 [No Abstract] [Full Text] [Related]
11. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
12. Early pharmacologic treatment in Parkinson's disease. Hauser RA Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870 [TBL] [Abstract][Full Text] [Related]
13. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?]. Defer GL Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847 [No Abstract] [Full Text] [Related]
14. Treatment options for early Parkinson's disease. Stacy M; Brownlee HJ Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572 [TBL] [Abstract][Full Text] [Related]
17. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Bonuccelli U; Del Dotto P; Rascol O Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]